Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhenium-188 lipiodol
- Development stage
- Unknown
- Lead developer
- International Atomic Energy Agency
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intra-arterial
01
Overview
Rhenium-188 lipiodol is a radiopharmaceutical agent used for the selective internal radiation therapy (SIRT) of inoperable hepatocellular carcinoma (HCC). It consists of the beta-emitting radioisotope rhenium-188 (188Re) complexed with a lipophilic chelating agent (such as HDD or DEDC) and dissolved in Lipiodol (ethiodized oil). Rhenium-188 is a high-energy beta emitter with a half-life of 16.9 hours, which also emits low-energy gamma rays suitable for imaging. Lipiodol acts as a carrier that is selectively retained in the neovasculature of liver tumors. When injected intra-arterially, the drug delivers targeted radiation directly to the tumor site while sparing healthy liver tissue. It is particularly valued in developing countries as a cost-effective alternative to yttrium-90 or iodine-131 therapies because rhenium-188 can be produced on-site using a tungsten-188/rhenium-188 generator.
- Brand names
- REK-1REK1REK 1
- Other names
- rhenium-188-labeled lipiodolrhenium188-labeled lipiodolrhenium 188-labeled lipiodol188Re-lipiodolrhenium-188 HDD/lipiodol
02
Targets
DNA
Beyond the preview
Go deeper on rhenium-188 lipiodol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhenium-188 lipiodol.